BioLineRx (BLRX) Gross Profit (2024 - 2025)
BioLineRx's (BLRX) quarterly Gross Profit came in at $154000.0 in Q4 2025, down 97.28% year-on-year from $5.7 million in Q4 2024, and down 55.1% quarter-over-quarter from $343000.0 in Q3 2025.
BioLineRx (BLRX) Gross Profit (2024 - 2025) Analysis & Trends
BioLineRx's Gross Profit history runs 2 years deep, the most recent figure standing at $154000.0 for Q4 2025.
- On a quarterly basis, Gross Profit fell 97.28% year-over-year to $154000.0 in Q4 2025; TTM through Dec 2025 was $950000.0, a 95.17% decrease from a year earlier, with the FY2025 full-year figure at $950000.0, down 95.17% from the prior year.
- Gross Profit slipped to $154000.0 in Q4 2025 per BLRX's latest filing, from $343000.0 in the prior quarter.
- Across five years, Gross Profit topped out at $5.7 million in Q4 2024 and bottomed at $154000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 343,000.00 |
| Sep 30, 2025 | 343,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 221,000.00 |
| Mar 31, 2025 | 221,000.00 |
| Dec 31, 2024 | 5.66 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.40 Mn |